Losartan-d6 (hydrochloride)

• UNSPSC Description:

  Losartan-d6 hydrochloride is deuterated labeled Losartan potassium (HY-17512A). Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.

• Target Antigen:

  Angiotensin Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Endocrinology; Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  OCC1=C(Cl)N=C(CCCC)N1C([2H])([2H])C2=CC=C(C3=C([2H])C([2H])=C([2H])C([2H])=C3C4=NNN=N4)C=C2.Cl

• Molecular Weight:

  465.41

• References & Citations:

  [1]Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.|[2]Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.|[3]Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.|[4]Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.|[5]Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported